The Protective Level of Serum Antibodies to the Capsular Polysaccharide of Haemophilus influenzae Type b

R. Kayhty, Heikki Peltola, Viena Karanko, +1

The Journal of Infectious Diseases

ImmunohematologyHumoral ResponseImmunologySerum AntibodiesCapsular Polysaccharide +16

The Elimination of Indigenous Measles, Mumps, and Rubella from Finland by a 12-Year, Two-Dose Vaccination Program

Heikki Peltola, Olli P. Heinonen, Martti Valle, +4

New England Journal of Medicine

Clinical Efficacy of Meningococcus Group A Capsular Polysaccharide Vaccine in Children Three Months to Five Years of Age

Heikki Peltola, P. Helena Mäkelä, Helena Käyhty, +8

New England Journal of Medicine

Efficacy of<i>Haemophilus Iinfluenzae</i>Type b Polysaccharide–Diphtheria Toxoid Conjugate Vaccine in Infancy

Juhani Eskola, Heikki Peltola, Aino K. Takala, +9

New England Journal of Medicine

VaccinationVaccine SafetyH. InfluenzaeOpen TrialVaccine Development +11

Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory.

Helena Käyhty, Viena Karanko, Heikki Peltola, +1

PubMed

First VaccinationImmunologySerum AntibodiesImmunodominanceImmunologic Tolerance +14

Serum Antibodies After Vaccination with <i>Haemophilus influenzae</i> Type b Capsular Polysaccharide and Responses to Reimmunization: No Evidence of Immunologic Tolerance or Memory

Helena Käyhty, Viena Karanko, Heikki Peltola, +1

PEDIATRICS

ImmunodeficienciesFirst VaccinationImmunologySerum AntibodiesImmunodominance +19

Serum Antibodies to Capsular Polysaccharide Vaccine of Group A Neisseria meningitidis Followed for Three Years in Infants and Children

Helena Käyhty, Viena Karanko, Heikki Peltola, +2

The Journal of Infectious Diseases

ANTIBODY LEVELS ACHIEVED IN INFANTS BY COURSE OF HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE/DIPHTHERIA TOXOID CONJUGATE VACCINE

Juhani Eskola, Heikki Peltola, P. Helena Mäkelä, +4

The Lancet

VaccinationVaccine DevelopmentImmunologyVaccine DesignPolyvalent Vaccine +2

RAPID EFFECT ON ENDEMIC MEASLES, MUMPS, AND RUBELLA OF NATIONWIDE VACCINATION PROGRAMME IN FINLAND

Heikki Peltola, Tapio Kurki, Martti Virtanen, +5

The Lancet

VaccinationPreventive MedicineVaccine DevelopmentVaccine EfficacyInfection Control +4

Increase of Vaccination Coverage by Mass Media and Individual Approach: Intensified Measles, Mumps, and Rubella Prevention Program in Finland

Mikko Paunio, Martti Virtanen, Heikki Peltola, +5

American Journal of Epidemiology

VaccinationPreventive MedicineHealth PolicyCombined MeaslesHealth Communication +11